List of Valtoco drug patents

Valtoco is owned by Neurelis Inc.

Valtoco contains Diazepam.

Valtoco has a total of 5 drug patents out of which 0 drug patents have expired.

Valtoco was authorised for market use on 10 January, 2020.

Valtoco is available in spray;nasal dosage forms.

Valtoco can be used as nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older.

The generics of Valtoco are possible to be released after 27 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265402 NEURELIS INC Absorption enhancers for drug administration
May, 2025

(2 years from now)

US9642913 NEURELIS INC Pharmaceutical composition including alkyl glycoside and an anti-seizure agent
May, 2025

(2 years from now)

US8927497 NEURELIS INC Absorption enhancers for intranasal administration
Jul, 2025

(2 years from now)

US8895546 NEURELIS INC Administration of benzodiazepine compositions
Mar, 2029

(6 years from now)

US11241414 NEURELIS INC Administration of benzodiazepine compositions
Mar, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jan 10, 2023
Orphan Drug Exclusivity (ODE) Jan 10, 2027

Drugs and Companies using DIAZEPAM ingredient

Market Authorisation Date: 10 January, 2020

Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older

Dosage: SPRAY;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic